The relation between life quality and subtype of the disease in patients with irritablebowel syndrome

Kayar, Yusuf; Ağın, Mehmet; Ünver, Nurcan; Dertli, Ramazan; Kırpınar, İsmet

doi:10.5455/annalsmedres.2019.01.035

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IBS pathophysiology is exceptionally complex since it involves different factors such as abnormal intestinal motility, visceral hyperalgesia, increased intestinal permeability, immune activation, altered intestinal microbiota, and disturbance in brain‐gut function 2 . Amongst people who meet clinical criteria for IBS diagnosis, symptoms severity varies over a broad spectrum, ranging from very mild to incapacitating, 4 which makes IBS patients have a worse quality of life when compared to the healthy population 5 …”

Section: Introductionmentioning

confidence: 99%

A novel distinctive form of identification for differential diagnosis of irritable bowel syndrome, inflammatory bowel disease, and healthy controls

Ramió‐Pujol¹,

Amoedo

Serra‐Pagès³

et al. 2020

GastroHep

View full text Add to dashboard Cite

Background Irritable bowel syndrome (IBS) is a functional disorder affecting around 11% of the world population, which diagnostic is mainly based on clinical parameters. IBS shares many symptoms with other gastrointestinal disorders such as inflammatory bowel disease (IBD), which makes positive diagnosis a difficult task. Aim This work presents the design of a new test, called RAID‐Dx, which is a mathematical algorithm based on the combination of nine faecal microbial markers capable of diagnosing IBS. Methods A cohort consisting of 165 subjects (52 IBS and 52 IBD patients, and 61 healthy controls) was recruited from the Gastroenterology Department of six hospitals. Each patient provided a stool sample from which DNA was extracted, and microbial markers composing RAID‐Dx were analysed by qPCR. The results obtained were used to define and validate the RAID‐Dx algorithm. Results The abundance of the biomarkers included in the algorithm differed according to the diagnosis. RAID‐Dx shows a high capacity to diagnose IBS with a sensitivity of 82.4% and a specificity of 85.7%. RAID‐Dx also reports higher sensitivity and specificity values than faecal calprotectin for IBS and IBD differentiation. Conclusions RAID‐Dx is a noninvasive tool aimed to diagnose IBS with high sensitivity and specificity. The use of this new tool for IBS diagnosis could significantly improve disease management, minimise its misdiagnosis and increase patients’ quality of life.

show abstract

Section: Introductionmentioning

confidence: 99%